Glycogen

Glycogen is a high-molecular-mass, hyperbranched homopolysaccharide of D-glucose that serves as the primary rapid-mobilization carbohydrate energy reserve in animals, fungi, and many bacteria. First isolated from mammalian liver tissue in 1857 by the French physiologist Claude Bernard—and enzymatically characterized in the 1930s and 1940s by Carl Ferdinand Cori and Gerty Theresa Cori, who received the 1947 Nobel Prize in Physiology or Medicine—glycogen consists of linear chains of α-D-glucopyranose residues joined by α-(1→4) glycosidic bonds, with α-(1→6) glycosidic branch points occurring every 8 to 12 glucose residues (roughly twice as frequently as the 24-to-30-residue branching interval of plant amylopectin).

In an adult human, major glycogen stores reside in two tissues with distinct physiological missions: the liver stores 80 to 120 grams of glycogen (constituting up to 6%–10% of wet liver mass after a carbohydrate-rich meal) to buffer systemic blood glucose homeostasis between meals and during overnight fasting, whereas skeletal muscle stores 300 to 500 grams of glycogen (approximately 1%–2% of muscle mass) as an intracellular fuel reserve that powers glycolysis and adenosine triphosphate (ATP) regeneration during muscular contraction. Smaller yet functionally important glycogen pools also reside in cardiac muscle, kidney, and brain astrocytes.

The Glycogenin Core and 12-Tiered β-Granule Geometry

At the center of every mature glycogen molecule lies a homodimer of glycogenin (37 kDa per monomer), a self-glucosylating glycosyltransferase enzyme that initiates de novo granule assembly by covalently attaching an oligoglucan primer of 8 to 13 α-(1→4)-linked glucose units to its own conserved Tyr195 phenolic hydroxyl group using UDP-glucose. From this central protein core, glucan chains radiate outward in concentric spherical layers (tiers). Each internal B-chain carries an average of two α-(1→6) branch points, whereas the outermost A-chains remain unbranched.

Mathematical modeling and cryo-electron microscopy demonstrate that because each concentric tier doubles the number of glucan chains while adding a radial thickness of ~1.9 nm, steric crowding at the outer surface limits a single β-granule to a maximum of 12 concentric tiers, corresponding to a diameter of ~42 nm, a molecular mass of ~10⁷ Da, and approximately 55,000 glucose residues. In this 12-tier architecture, the outermost tier (Tier 12) alone contains ~2,048 non-reducing chain ends and houses roughly 50% of the total glucose residues of the entire macromolecule. In hepatocytes, 20 to 40 individual β-granules further associate into rosette-shaped α-granules measuring up to 200–300 nm in diameter.

Osmotic Inertness and Kinetic Multiplication of Non-Reducing Ends

Evolutionary selection for glycogen's hyperbranched architecture reflects two quantitative biophysical constraints:

1. Prevention of Osmotic Cell Lysis: In a well-fed hepatocyte, the total glucose stored inside glycogen equals an effective monomeric concentration of ~0.4 M (400 mM). If 400 mM of free D-glucose were dissolved in the cytosol, the van 't Hoff osmotic pressure (Π = MRT ≈ 10 atm at 37 °C) would exceed extracellular plasma osmolarity (~300 mOsm/L), driving massive osmotic water influx and rupturing the cell membrane. Packaging 55,000 glucose units into insoluble, hydrated polymeric granules reduces the cytosolic molar concentration of glycogen particles to ~0.01 μM, rendering the energy reserve osmotically inert.
2. Simultaneous Enzymatic Mobilization: Both glycogen synthase and glycogen phosphorylase act exclusively at the non-reducing ends (free C4–OH groups) of glucan chains. Whereas an unbranched linear chain of 55,000 glucose units possesses only one non-reducing end and one reducing end (sequestered on glycogenin Tyr195), a 12-tier glycogen β-granule presents >2,000 non-reducing ends simultaneously on its outer surface, allowing dozens of phosphorylase dimers to cleave glucose units in parallel within milliseconds of adrenergic or glucagon stimulation.

Glycogenesis: UDP-Glucose Activation, Elongation, and Branching

Synthesis of glycogen (glycogenesis) from glucose-6-phosphate (G6P) requires three coordinated enzymes and consumes one high-energy uridine triphosphate (UTP) equivalent per glucose incorporated:

1. Phosphoglucomutase reversibly isomerizes G6P to glucose-1-phosphate (G1P) via a glucose-1,6-bisphosphate intermediate.
2. UDP-glucose pyrophosphorylase condenses G1P with UTP to generate the activated nucleotide sugar donor uridine diphosphate glucose (UDP-glucose) plus inorganic pyrophosphate (PP_i). Subsequent hydrolysis of PP_i → 2 P_i by inorganic pyrophosphatase (Δ*G*°' = −19.2 kJ/mol) renders UDP-glucose formation thermodynamically irreversible in vivo.
3. Glycogen synthase transfers the glucosyl moiety from UDP-glucose to the C4 hydroxyl group at a non-reducing end, forming an α-(1→4) linkage and releasing UDP (which nucleoside diphosphate kinase rephosphorylates using ATP). Once a linear chain reaches at least 11 residues, glycogen branching enzyme (amylo-(1,4→1,6)-transglycosylase) cleaves a terminal block of 6 to 8 α-(1→4)-linked residues and reattaches it via an α-(1→6) bond to an interior C6 hydroxyl group at least 4 residues away from an existing branch point.

Glycogenolysis: Phosphorolysis and Bifunctional Debranching

Degradation of glycogen (glycogenolysis) is not a simple reversal of synthesis; instead, it is catalyzed by glycogen phosphorylase, a homodimeric enzyme that utilizes pyridoxal 5'-phosphate (PLP, vitamin B₆) as an essential acid–base prosthetic cofactor. Rather than hydrolyzing α-(1→4) bonds with H₂O, glycogen phosphorylase uses inorganic orthophosphate (P_i) to cleave terminal residues via phosphorolysis ( via a resonance-stabilized oxocarbenium ion intermediate), releasing glucose-1-phosphate (G1P):

`` Glycogen (n residues) + Pᵢ ⇌ Glycogen (n - 1 residues) + Glucose-1-phosphate (ΔG°' = +3.1 kJ/mol) ``

Because the intracellular [P_i]/[G1P] ratio exceeds 30:1 to 100:1, mass action drives phosphorolysis forward in vivo. Phosphorolysis provides a crucial bioenergetic advantage: the released G1P is isomerized by phosphoglucomutase directly into glucose-6-phosphate (G6P) without expending a molecule of ATP via hexokinase, elevating the net glycolytic yield from 2 ATP (for free glucose) to 3 ATP per glucosyl residue mobilized from glycogen.

Because steric hindrance halts glycogen phosphorylase 4 residues away from any α-(1→6) branch point (forming a "limit dextrin"), a single eukaryotic bifunctional polypeptide—glycogen debranching enzyme (AGL)—completes mobilization: its 4-α-glucanotransferase domain shifts a trisaccharide block of three α-(1→4) residues from the stub onto a neighboring linear chain, and its amylo-α-1,6-glucosidase domain hydrolyzes the single remaining α-(1→6)-linked glucose residue with water, releasing free D-glucose (accounting for ~8%–10% of mobilized glycogen units).

Kinase and Phosphatase Cascades: Insulin vs. Glucagon and Epinephrine

To prevent a futile cycle between simultaneous synthesis and breakdown, glycogen synthase and glycogen phosphorylase are reciprocally regulated by both allosteric regulation and reversible covalent phosphorylation:

• Catabolic Fasting or Fight-or-Flight State (Glucagon & Epinephrine): Binding of glucagon (in liver) or epinephrine (in liver and muscle) to G_s-coupled GPCRs activates adenylyl cyclase to produce the second-messenger cyclic AMP (cAMP), which activates Protein Kinase A (PKA). PKA (together with Ca²⁺/calmodulin during muscle excitation–contraction coupling) activates phosphorylase kinase, which phosphorylates Ser14 on inactive glycogen phosphorylase b (T-state), converting it into active glycogen phosphorylase a (R-state). Simultaneously, PKA (along with GSK3) phosphorylates active glycogen synthase a at multiple serine residues, converting it into inactive glycogen synthase b.
• Anabolic Fed State (Insulin): Postprandial insulin signaling activates Protein Phosphatase 1 (PP1) (targeted to glycogen granules by its G_M or G_L regulatory subunit) and inhibits GSK3 via the PI3K–Akt pathway. PP1 dephosphorylates and inactivates phosphorylase kinase and glycogen phosphorylase a (enhanced allosterically in hepatocytes by free glucose binding to phosphorylase a), while dephosphorylating and activating glycogen synthase b (further stimulated allosterically by rising G6P).

Why can the liver release glucose into the bloodstream while skeletal muscle cannot?

Phosphorolysis of glycogen and subsequent isomerization by phosphoglucomutase produces glucose-6-phosphate (G6P), which carries a negative phosphate charge and cannot cross the cell membrane via GLUT transporters. Hepatocytes (and renal proximal tubule cells) express glucose-6-phosphatase (G6PC1) on the luminal face of the endoplasmic reticulum, which hydrolyzes G6P to free glucose and P_i for export into the blood via GLUT2. Skeletal myocytes completely lack glucose-6-phosphatase, ensuring that muscle glycogen is retained strictly for local glycolysis and muscle contraction.

Why does mobilizing glucose from glycogen yield 3 net ATP in glycolysis instead of 2 ATP?

When free blood glucose enters a muscle cell, hexokinase must consume one molecule of ATP to phosphorylate glucose to glucose-6-phosphate (G6P), leaving a net glycolytic yield of 2 ATP (4 ATP produced minus 2 ATP invested). When glycogen is degraded by glycogen phosphorylase, inorganic phosphate (P_i) attacks the α-(1→4) glycosidic bond directly to form G1P, which converts to G6P without ATP consumption. Because the hexokinase step is bypassed, only 1 ATP is invested (at PFK-1) while 4 ATP are produced, yielding 3 net ATP per glucosyl unit.

What causes Pompe disease (Glycogen Storage Disease Type II) if cytosolic glycogen phosphorylase is normal?

In addition to cytosolic phosphorolysis, roughly 1% to 3% of cellular glycogen is continuously engulfed into lysosomes via glycophagy (selective autophagy) and hydrolyzed to free glucose by the lysosomal enzyme acid α-glucosidase (GAA, acid maltase). In Pompe disease (GSD Type II), autosomal recessive mutations in GAA abolish lysosomal glycogen hydrolysis while cytosolic glycogen metabolism remains intact, causing progressive intralysosomal glycogen accumulation that disrupts myofibrillar architecture and leads to hypertrophic cardiomyopathy and respiratory muscle weakness.

1. Cori, C. F., & Cori, G. T. (1947). "Polysaccharide phosphorylase." Nobel Lectures, Physiology or Medicine 1942–1962, 186–206. https://doi.org/10.1016/S0021-9258(18)72416-272416-2)
2. Roach, P. J., Depaoli-Roach, A. A., Hurley, T. D., & Tagliabracci, V. S. (2012). "Glycogen and its metabolism: Some new developments and old themes." Biochemical Journal, 441(3), 763–787. https://doi.org/10.1042/BJ20111416
3. Meléndez-Hevia, E., Waddell, T. G., & Shelton, E. D. (1993). "Optimization of molecular design in the evolution of metabolism: The glycogen molecule." Biochemical Journal, 295(2), 477–483. https://doi.org/10.1042/bj2950477
4. Adeva-Andany, M. M., González-Lucán, M., Donapetry-García, C., Fernández-Fernández, C., & Ameneiros-Rodríguez, E. (2016). "Glycogen metabolism in humans." BBA Clinical, 5, 85–100. https://doi.org/10.1016/j.bbacli.2016.02.001